Vivace Therapeutics Secures $35 Million in Series D Financing for Cancer Therapies Development

Vivace Therapeutics concludes a $35 million Series D funding round to support the clinical advancement of promising cancer therapy VT3989.

AI-assisted, human-published

Latest headlines

Join us for funding and investment opportunities.

Stay connected!

If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here